Prosta LUCC Cohort

Project background & objectives

Each year, between 50,000 and 60,000 men are diagnosed with prostate cancer. In 2017, the estimated prevalence in France was 643,156 people, making prostate cancer one of the most common cancers in men. This cohort is based on a standardized data model applicable to all types of cancer or oncology specialties (surgery, medical oncology, radiation oncology, pathology, radiology, etc.) in order to facilitate the use of these data for clinical and research purposes.

The main objective of the Prosta LUCC (Large & Unified Cancer Cohort) cohort is to better understand the progression of prostate cancer and accelerate therapeutic innovation for the benefit of affected patients. A secondary objective is to evaluate and optimize the artificial intelligence algorithms used to automatically collect data from your medical records, which will improve the performance of these tools.

Cohort initiated by the Doctors:

Alice Bernard Tessier - Data Controller, Gustave Roussy
Constance Thibault, George Pompidou European Hospital
Guilhem Roubaud, Bergonié Institute

+50 000

Men diagnosed each year

The patient's voice

The Patients en Réseau association brings together patients and relatives affected by cancer, and was created on the basis of their experiences. Meet the Patients en Réseau association

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Participating centers

No items found.

Inclusion criteria & study variables

The Prosta LUCC cohort is open to all types of institutions and includes patients at any stage of the disease. To be eligible for inclusion in the study, patients must meet the following criteria:

Present cancerous lesions established by histological examination;
Have received medical, surgical, or any other treatment related to prostate cancer at one of the institutions participating in the study;
Not having objected to the collection, storage, and processing of personal data concerning health.

‍

In order to provide the most comprehensive picture possible of patients with prostate cancer, the cohort includes numerous variables covering the following areas:

Genre,
Date of birth,
vital status,

FAMILY NUMBER,
puberty etc...

FAMILY HISTORY OF AOH,
comorbidities,
AFFECTED FAMILY MEMBER(S) ETC...

DIAGNOSIS DATE,
DATE OF 1ST EXPERIMENT,
type of hereditary angioedema,

NATURE OF DEFICIT C1NH,
BIOLOGICAL CHECK-UP, ETC.

TREATMENT NAME,
DOSE,
FREQUENCY OF ADMINISTRATION,

SIDE EFFECT(S) ETC...

LOCATION OF THE CRISIS,
TRIGGERING FACTOR,
DURATION OF THE CRISIS,

TYPE OF TREATMENT,
treatment efficacy etc...

TYPE OF INTERCURRENT EVENT,
SHORT-TERM PROPHYLACTIC TREATMENT,
INTERCURRENT EVENT FOLLOWED BY A CRISIS ETC...

Genre,
Date of birth,
vital status,

DATE OF DEATH,
Cause of death etc...

SMOKING STATUS,
consumption of canNabis,
vital status

DIAGNOSIS DATE,
METASTATIC AT DIAGNOSIS,
TNM STATUS AT DIAGNOSIS,

HISTOLOGICAL SUBTYPE,
metastatic sites,
MUTATIONS etc...

TYPE OF TREATMENT,
drugs used,
BETTER RESPONSE TO TREATMENT,

PROGRESSION ETC...

Genre,
Date of birth,
vital status,

DATE OF DEATH,
Cause of death etc...

DIAGNOSIS DATE,
METASTATIC AT DIAGNOSIS,
TNM STATUS AT DIAGNOSIS,

HISTOLOGICAL SUBTYPE,
metastatic sites,
MUTATIONS etc...

TYPE OF TREATMENT,
drugs used,
BETTER RESPONSE TO TREATMENT,

PROGRESSION ETC...

Genre,
Date of birth,
vital status,

DATE OF DEATH,
WEIGHT MEASUREMENT
GROWTH etc...

DIAGNOSIS DATE,
METASTATIC AT DIAGNOSIS,
TNM STATUS AT DIAGNOSIS,

HISTOLOGICAL SUBTYPE,
metastatic sites,
MUTATIONS etc...

TYPE OF TREATMENT,
drugs used,
BETTER RESPONSE TO TREATMENT,

PROGRESSION ETC...

AGE,
SIZE,
WEIGHT,

SMOKING (PACKAGE/YEAR),
Allergies etc...

Patient with ENT symptoms,
cardiovascular disease,
nasosinus polyposis, etc...

Bronchodilator treatment(s),
NAME of bronchodilator,
dose of bronchodilator,

bronchodilator frequency etc...

Assessment of the number of exacerbations,
number of exacerbations,
reason for hospitalization etc...

GENRE,
DATE OF BIRTH,
vital status,

SMOKING (PACKAGE/YEAR),
Allergies etc...

SMOKING STATUS
ONCOLOGICAL HISTORY ETC...

Evaluation of eva,
Evaluation of das-28,
Anti-ccp ac results (u/ml),

Biopsy results etc...

symptomatic treatments
fund processing
biotherapies

stopping treatment etc...

GENRE,
DATE OF BIRTH,
comorbidities,

Size in cm,
WEIGHT etc...

ASSESSMENT OF SYMPTOMATOLOGY,
VALUATION DATE,
claudication ETC...

DATE OF INTERVENTION,
type of anesthesia,
existence of a puncture,

LOCATION OF PUNCTURE,
EXISTENCE OF AN ARTHÉRIOGRAPHIC BALANCE SHEET etc...

POST-OPERATIVE FOLLOW-UP DATE,
PRESENCE OF A COMPLICATION,
LOCATION OF COMPLICATION,

DEATHS etc...

HOSPITALIZATION,
DATE OF ADMISSION TO HOSPITAL,
HOSPITAL DISCHARGE DATE,

COMPLICATIONS DURING HOSPITALIZATION etc...

Scientific Committee

No items found.

Key dates

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Posters & Publications

No items found.

Research projects

Here you will find all the study projects using the cohort. These projects comply with the regulatory framework and have been approved in advance by the cohort's scientific committee:

HARMON-IA : Cohorte rétrospective multicentrique de patients atteints d'un cancer de la prostate métastatique en France (1200 patients, 15 centres). Partenaires : DALI, FIAC, Pfizer, Novartis

‍

Patients

Why take part in the project?

Some of your medical and administrative data is collected when you are treated in a healthcare facility. This data is useful for the advancement of research.

This research, conducted in the public interest, aims to develop knowledge in order to develop new treatments or improve the overall management of patients suffering from the same disease as you. If you agree to your data being used for this study, you will not have to make any additional visits or undergo any additional examinations.

Only information already in your medical file will be collected. No directly identifying data (surname, first name or contact details) will be included in the cohorts.